

---

NH Theraguix, a biotech company (drug/oncology sector) located in Meylan (Grenoble area) recruits as soon as possible, a:

Scientist specialized in Medical Imaging (CDI)

Your mission will directly concern the analysis of the MRI data issued from on-going clinical trials managed by the company, in order to monitor, analyze and understand the efficacy of AGuiX, the candidate drug developed by the company, as a theranostic agent.

Especially you will :

1- Analyze MRI data issued from clinical trials. This includes :

- Collection of radiological images (MRI) acquired during clinical trials
- Image quality control and contact with investigator sites to resolve detected quality problems
- Qualitative and quantitative analyzes of MRIs (contrast enhancement linked to the experimental drug, quantification, etc.) and representation of the results
- Understanding and interpretation of the results
- Writing of image processing and reporting reports

2- Optimize and improve the MRI analysis process. This includes :

- Determination of points to be improved to reduce the analysis time
- Definition of needs in terms of software evolution in order to have a more efficient image analysis protocol, ...
- If necessary, establishment of a specification "Adaptation to needs" with the software supplier and monitoring of the optimization
- Development of algorithms (quantification, extraction and use of MRI data, etc.)

Internally, you will work in close collaboration with the clinical development unit, and the scientific collaborators of the company (biophysicists specialized in MRI, chemists, biologists). You will also interact with Cancer Centers and University Hospitals in France but also Europe and USA.

**Profile:** You are a young PhD doctor, specialized in the field of MRI and imaging analysis with a strong background in physics/mathematics and knowledge in medicine (oncology, radiology and MRI, contrast agents). You wish to work in industry, and you have a sense of initiative and a flexibility as appropriate for a growing start-up with no routine. You are comfortable in English, you have a sense of organization and rigor appropriate for adapting to the quality assurance policy of the company.

Contact: Géraldine Le Duc, CEO - [leduc@nhtheraguix.com](mailto:leduc@nhtheraguix.com)

**About the company**

*NH TherAguix is a clinical-phase French start-up based in Grenoble, which was created in 2015 by two scientists: Géraldine Le Duc and Olivier Tillement. The company develops a bimodal nanodrug (AGuIX®) with a radiosensitizing effect and visible in MRI. AGuIX® is an innovative nanoparticle that has demonstrated a good post-injection tolerance and early evidence of radiosensitization when combined with radiotherapy in patients with brain metastases (NANORAD1 Phase 1b trial, CHU Grenoble). At present, 2 Phase 2 trials in brain metastases are recruiting: NANORAD2 as a multicentric French trial is piloted by CHUGA, combining whole brain radiotherapy and AGuIX intravenous injection (22 pats/100 treated). NANOSTEREO as a multicentric French trial is piloted by Centre Léon Bérard and inclusions are starting (2/55 patients treated). In this particular trial, stereotactic radiosurgery is combined with AGuIX intravenous injection. In parallel, a Phase 1b trial for advanced cervical cancer (NANOCOL) is underway at Institut Gustave Roussy in Paris (6/12 patients). AGuIX® technology is supported by 12 patents and 60+ scientific publications. The manufacturing of AGuIX batches is ensured by partners such as Sanofi and Carbogen. The company raised €13M on March 18<sup>th</sup>, 2019 through venture capital funds (BPI Innobio2, Arbevel, Omnes, Supernova) and €2M as non dilutive funds. The team is presently composed of 15 persons.*